



EUROPEAN
SOCIAL INSURANCE
PLATFORM

The Social Insurers of Europe

Trans-border patient rights – latest EU developments

EUMASS Seminar on 8 February 2013 in Brussels


The European Social Insurance Platform: Who we are and what we do

- A strategic alliance of over 40 national statutory social security organisations (healthcare, pensions, accidents-at work and occupational diseases, family allowances, unemployment insurances) in 15 EU Member States, Croatia and Switzerland.
- ESIP's mission is to preserve high profile social security for Europe, to reinforce solidarity based social insurance systems, and to maintain European social protection quality.
- ESIP is based in Brussels at the „Maison européenne de la Protection Sociale“ (www.esip.org) together with other organisations active in the field of social protection at European level.

Cross-border health care treatment: Patient has 2 options

- **EU Regulation 883/2004/ European Health Insurance Card, EHIC (April 2004):** provides “benefits in kind”; the patient does not bear any financial risk. Problem: some health professionals/hospitals in various countries refuse treatment using EHIC.
- **EU Directive on Patient’s Rights to Cross-border Health Care (March 2011):** provides “benefits in cash”; the patient bears a considerable financial risk: Reimbursement is limited to the level covered by health care system of the country of origin.
- **In both cases (EHIC and Directive):** Planned cross-border hospital treatment or treatment requiring use of highly specialised and cost-intensive equipment always requires **prior authorisation** of the health care system of the country of origin (only in cases of emergency prior authorisation is unnecessary).

The practical relevance of the Directive for the patient

- **Limited consequences** for patients living in countries where the local offer of health care is inadequate or not accessible without backhanders.
 - Patients from a low-cost environment (e.g. Bulgaria) seeking cross-border treatment in a high-cost health care system (e.g. Austria or Germany) have to pay the full price for high-cost care and receive **reimbursement only of the amount of coverage in the low-cost system**.
 - This situation will remain unchanged in the near future. **Disparities** between economically potent and weaker countries in the EU **will probably even sharpen**, particularly during the ongoing debt crisis.
- 

Transposition of the Directive on Patient's Rights to Cross-border health care (1)

- Member States have to transpose the Directive by 25 October 2013

Important Changes:

- **National Contact Points for cross-border healthcare**
- Each Member State shall designate contact points for cross-border healthcare.
- These contact points shall consult with **patient associations, healthcare providers and healthcare insurers**. They are responsible for providing patients with information on their rights, the reimbursement and conditions of treatment when they decide to take advantage of cross-border healthcare.
- Member States decide whether to assign this task to healthcare providers or other private or public institutions.

Transposition of the Directive on Patient's Rights to Cross-border health care (2)

- **European Reference Networks (ERN)**
- ERN should reflect the need for **services and expertise** to be distributed across the EU and help professionals and centers of expertise to exchange and to share their knowledge.
- The aim is in particular **to improve the diagnosis of rare and specific diseases**, updating and contributing to the latest scientific findings, treating patients from other Member States and ensuring the availability of subsequent treatment facilities where necessary.
- **Common rules on medical prescriptions**
- **Minimum list of elements** to be included in a **medical prescription** taken by a patient travelling from one EU country to another. Provisions for a common way to identify the patient, the prescriber and the prescribed.
- Important for **patients with chronic diseases** wishing to travel to another country, for **patients living in border regions**, or for **patients with a rare disease**, where the best expertise can be found across a border.